UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 30, 2004
--------------------------
GENELABS TECHNOLOGIES, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 0-19222 94-3010150
- -------------------------------------------------------------------------------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
505 Penobscot Drive, Redwood City, California 94063
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 369-9500
----------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
2.02 Results of Operations and Financial Condition
On December 30, 2004, Registrant updated its financial outlook for
year-end 2004. A press release relating to this update is furnished as exhibit
99.1 hereto.
The information in item 2.02 of this Form 8-K (including the related
sections of Exhibit 99.1) shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
8.01 Other Events
On December 30, 2004, Registrant announced that it had received
$1.25 million from Affymetrix Inc. for amending a non-exclusive license to
Registrant's Linker-Aided DNA Amplification technology. The amendment converts
the license to a fully paid up non-exclusive license and eliminates royalties
and fees that were payable under the original agreement.
9.01 Financial Statements and Exhibits
(c) Exhibits.
99.1 Press Release of Registrant, dated December 30, 2004, entitled
"Genelabs Technologies Receives $1.25 Million from Affymetrix for
Amendment to Non-Exclusive License for DNA Amplification Technology"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereto duly authorized.
GENELABS TECHNOLOGIES, INC.
By: /s/ James A.D. Smith
---------------------------------
Name: James A.D. Smith
Title: President and Chief Executive
Officer
Date: January 3, 2005
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
99.1 Press Release of Registrant, dated December 30, 2004,
entitled "Genelabs Technologies Receives $1.25 Million
from Affymetrix for Amendment to Non-Exclusive License
for DNA Amplification Technology"